---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-005038"
form_type: "8-K"
ticker: null
cik: "0000786947"
company_name: "ACURA PHARMACEUTICALS, INC"
filed_at: "2026-01-20T23:59:59+00:00"
generated_at: "2026-05-16T09:40:17.851219+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# Acura receives $300K loans from controlling shareholder; warns of potential shutdown if no funding by Jan 2026

## Summary
- On Dec 31, Jan 2, and Jan 16, 2026, Acura received $100K each from Abuse Deterrent Pharma (65% owner), bringing note principal to $9.59M.
- Note bears 5.25% interest; default rate 7.5%; events of default include bankruptcy and failure to pay within 5 days.
- Company states that without additional financing by end of January 2026, it will scale back operations or seek bankruptcy protection.
- AD Pharma holds ~65% of Acura's common stock; entity controlled by Mr. Schutte, who directly owns ~13%.
- Proceeds fund day-to-day operations; company warns of potential complete loss of shareholder value.

## SEC filing metadata
- accession: 0001104659-26-005038
- form_type: 8-K
- cik: 0000786947
- company_name: ACURA PHARMACEUTICALS, INC
- filed_at: 2026-01-20T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 1.01, 2.01, 2.03, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/786947/000110465926005038/0001104659-26-005038-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/786947/000110465926005038/tm263622d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-005038
- JSON: https://secwatch.observer/filing/0001104659-26-005038.json
- Plain text: https://secwatch.observer/filing/0001104659-26-005038.txt

## Key facts
- Debt Financings
  ACURA PHARMACEUTICALS, INC incurred loan of $100,000 with Abuse Deterrent Pharma, LLC at 5.25%.
  - Instrument: loan
  - Principal: $100,000
  - Counterparty: Abuse Deterrent Pharma, LLC
  - Rate: 5.25%
  - Event: incurrence
  source text: On each of December 31, 2025, January 2, 2026 and January 16, 2026 we received loans of $100,000 from Abuse Deterrent Pharma, LLC ("AD Pharma").
  evidence_url: https://www.sec.gov/Archives/edgar/data/786947/000110465926005038/0001104659-26-005038-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.